| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |